TY - JOUR
T1 - Safety and efficacy of melatonin as an adjuvant therapy in COVID-19 patients
T2 - Systematic review and meta-analysis
AU - Mohamed Taha, Amira
AU - Adel Abdelkader Saed, Sara
AU - Hossam-Eldin Moawad, Mostafa
AU - Abd El-Tawab Moawad, Wesam
AU - Al-hejazi, Tala
AU - Mousa, Yosra
AU - Sharma, Ramaswamy
AU - Reiter, Russel J.
N1 - Publisher Copyright:
© 2023
PY - 2023/9
Y1 - 2023/9
N2 - Background: Melatonin might be beneficial to coronavirus disease 2019 (COVID-19) patients in terms of both prevention and treatment. We investigated how melatonin affected various clinical and laboratory results in COVID-19 patients. Methods: PubMed, Scopus, Cochrane Library and Web of Science databases were utilized for searching eligible articles fulfilling our inclusion criteria up to December 2022. We used random effect model in case of significant heterogeneity; in other cases, a fixed model was applied. RevMan was used for meta-analysis. Results: We included 11 studies in our review. Clinical improvement rate was found to be statistically significantly higher in patients taking melatonin than in the control group (OR: 5.09; 95% CI: 2.60−9.96, p < 0.001). Patients receiving melatonin showed a non-significant difference in mortality rate compared to the control group (OR: 0.37; 95% CI: 0.07−1.81, p = 0.22). However, in the randomized controlled trials subgroup, melatonin-treated patients showed significantly lower mortality than did the controls (OR: 0.17; 95% CI: 0.08−0.38, p < 0.001). CRP level was statistically significantly lower due to melatonin treatment (weighted mean difference [WMD] = −9.85; 95% CI: −18.54 to −1.16, p = 0.03). Length of hospital stay was statistically significantly shorter in patients taking melatonin compared to controls (WMD = −4.05; 95% CI: −5.39 to −2.7, p < 0.001). Conclusion: Melatonin was found to have substantial effects on COVID-19 patients when used as adjuvant therapy, enhancing clinical improvement and decreasing time to recovery with a shorter length of hospital stay and a shorter duration of mechanical ventilation.
AB - Background: Melatonin might be beneficial to coronavirus disease 2019 (COVID-19) patients in terms of both prevention and treatment. We investigated how melatonin affected various clinical and laboratory results in COVID-19 patients. Methods: PubMed, Scopus, Cochrane Library and Web of Science databases were utilized for searching eligible articles fulfilling our inclusion criteria up to December 2022. We used random effect model in case of significant heterogeneity; in other cases, a fixed model was applied. RevMan was used for meta-analysis. Results: We included 11 studies in our review. Clinical improvement rate was found to be statistically significantly higher in patients taking melatonin than in the control group (OR: 5.09; 95% CI: 2.60−9.96, p < 0.001). Patients receiving melatonin showed a non-significant difference in mortality rate compared to the control group (OR: 0.37; 95% CI: 0.07−1.81, p = 0.22). However, in the randomized controlled trials subgroup, melatonin-treated patients showed significantly lower mortality than did the controls (OR: 0.17; 95% CI: 0.08−0.38, p < 0.001). CRP level was statistically significantly lower due to melatonin treatment (weighted mean difference [WMD] = −9.85; 95% CI: −18.54 to −1.16, p = 0.03). Length of hospital stay was statistically significantly shorter in patients taking melatonin compared to controls (WMD = −4.05; 95% CI: −5.39 to −2.7, p < 0.001). Conclusion: Melatonin was found to have substantial effects on COVID-19 patients when used as adjuvant therapy, enhancing clinical improvement and decreasing time to recovery with a shorter length of hospital stay and a shorter duration of mechanical ventilation.
KW - Adjuvant
KW - COVID-19
KW - Efficacy
KW - Melatonin
UR - http://www.scopus.com/inward/record.url?scp=85171540944&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85171540944&partnerID=8YFLogxK
U2 - 10.1016/j.advms.2023.09.007
DO - 10.1016/j.advms.2023.09.007
M3 - Review article
C2 - 37742478
AN - SCOPUS:85171540944
SN - 1896-1126
VL - 68
SP - 341
EP - 352
JO - Advances in medical sciences
JF - Advances in medical sciences
IS - 2
ER -